Starlake Bioscience Co Inc Zhaoqing Guangdong (SHG:600866) — Market Cap & Net Worth
Market Cap & Net Worth: Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)
Starlake Bioscience Co Inc Zhaoqing Guangdong (SHG:600866) has a market capitalization of $1.02 Billion (CN¥6.98 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #8896 globally and #2183 in its home market, demonstrating a -2.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Starlake Bioscience Co Inc Zhaoqing Guangdong's stock price CN¥4.20 by its total outstanding shares 1661472616 (1.66 Billion). Also see Starlake Bioscience Co Inc Zhaoqing Guan assets under control for a full breakdown of the balance sheet.
Starlake Bioscience Co Inc Zhaoqing Guangdong Market Cap History: 2015 to 2026
Starlake Bioscience Co Inc Zhaoqing Guangdong's market capitalization history from 2015 to 2026. Data shows change from $2.00 Billion to $1.02 Billion (-5.28% CAGR). Also see 600866 cash flow metrics for how efficiently the company converts equity into cash flow.
Starlake Bioscience Co Inc Zhaoqing Guangdong Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Starlake Bioscience Co Inc Zhaoqing Guangdong's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Starlake Bioscience Co Inc Zhaoqing Guan stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.11x
Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.73x
Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap is 1.73 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.72 Billion | $679.85 Million | $24.31 Million | 2.53x | 70.82x |
| 2017 | $1.12 Billion | $686.97 Million | -$158.27 Million | 1.63x | N/A |
| 2018 | $763.41 Million | $859.11 Million | $42.28 Million | 0.89x | 18.06x |
| 2019 | $1.08 Billion | $1.05 Billion | $149.55 Million | 1.03x | 7.22x |
| 2020 | $1.21 Billion | $1.12 Billion | $148.71 Million | 1.09x | 8.16x |
| 2021 | $1.52 Billion | $4.07 Billion | $152.14 Million | 0.37x | 9.97x |
| 2022 | $1.44 Billion | $17.49 Billion | $608.33 Million | 0.08x | 2.37x |
| 2023 | $1.13 Billion | $17.37 Billion | $677.95 Million | 0.07x | 1.67x |
| 2024 | $1.57 Billion | $17.33 Billion | $943.15 Million | 0.09x | 1.67x |
| 2025 | $1.69 Billion | $15.90 Billion | $978.89 Million | 0.11x | 1.73x |
Competitor Companies of 600866 by Market Capitalization
Companies near Starlake Bioscience Co Inc Zhaoqing Guangdong in the global market cap rankings as of September 24, 2026. Review Starlake Bioscience Co Inc Zhaoqing Guan tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Starlake Bioscience Co Inc Zhaoqing Guangdong by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Starlake Bioscience Co Inc Zhaoqing Guangdong Historical Marketcap From 2015 to 2026
Between 2015 and today, Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap moved from $2.00 Billion to $ 1.02 Billion, with a yearly change of -5.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.02 Billion | -39.57% |
| 2025 | CN¥1.69 Billion | +7.42% |
| 2024 | CN¥1.57 Billion | +38.84% |
| 2023 | CN¥1.13 Billion | -21.42% |
| 2022 | CN¥1.44 Billion | -4.97% |
| 2021 | CN¥1.52 Billion | +25.05% |
| 2020 | CN¥1.21 Billion | +12.39% |
| 2019 | CN¥1.08 Billion | +41.40% |
| 2018 | CN¥763.41 Million | -31.74% |
| 2017 | CN¥1.12 Billion | -35.03% |
| 2016 | CN¥1.72 Billion | -13.97% |
| 2015 | CN¥2.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Starlake Bioscience Co Inc Zhaoqing Guangdong was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.02 Billion USD |
| MoneyControl | $1.02 Billion USD |
| MarketWatch | $1.02 Billion USD |
| marketcap.company | $1.02 Billion USD |
| Reuters | $1.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and selling food additives, feed additives, pharmaceutical intermediates, active pharmaceutical ingredients, organic fertilizers, and bio-based new materials. It operates through three main business lines: food and feed additives, biochemical raw materials and pharmaceutical intermediates, and organic fertilizers. The com… Read more